Project Grant R21NS139480
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$472K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders, will fund research to dissect the cellular and molecular composition of the glioblastoma (GBM) tumor microenvironment. The $687,279 award to Beth Israel Deaconess Medical Center, Inc. aims to characterize the evolution of neoplastic and immune cells in GBM during standard-of-care therapy, leveraging...
This Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research focused on understanding how endogenous dendritic cells drive T cell activation and expansion in glioblastoma, an aggressive form of brain cancer. The award, totaling $628,373.00, will be provided to The General Hospital Corporation, doing business...
This $111,666 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the role of the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) on microglia and macrophages in gliomas, a common and aggressive form of brain cancer. The primary research objectives are to use mouse models to investigate how TREM2 expression on...
This $420,251 Project Grant awarded on May 6, 2025 by the National Institute of Neurological Disorders and Stroke (CFDA 93.853) supports research on the development of encapsulated cell-based oncolytic virus therapy for glioblastoma (GBM), the most lethal primary brain tumor. The award recipient, Brigham & Women's Hospital Inc., will utilize mesenchymal stem cells (MSCs) engineered to express oncolytic herpes simplex virus (OHSV) variants in combination with immune-modulators like...
This federal Project Grant award of $659,325 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), supports research to investigate neuro-immune mechanisms in mutant IDH1 gliomas. The project, awarded to the Regents of the University of Michigan, focuses on molecular profiling of gliomas to better understand their pathophysiology. Key objectives include identifying...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,064,642 to Tufts Medical Center Parent, Inc. to conduct research on the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling pathway in regulating glioma stem cell properties and preventing recurrence of glioblastoma (GBM), a deadly form of brain cancer. The research aims to characterize how the ANG-PLXNB2 axis promotes small RNA biogenesis, particularly tRNA-derived...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $652,751 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Mayo Clinic to develop antibody drug conjugates (ADCs) designed to enhance the therapeutic window for treating glioblastoma (GBM), the most common and lethal primary brain cancer. The 5-year project, running from August 2025 to April 2030, will build on Mayo Clinic's previous research...
The Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $417,858 to Brigham & Women's Hospital, a nonprofit hospital and research institution affiliated with Harvard Medical School, for developing and evaluating a novel therapeutic approach using engineered mesenchymal stem cells (MSCs) to target brain tumors called glioblastomas (GBM). The MSCs are engineered to release bi-specific T-cell engager (BiTEs) that simultaneously target multiple...
This federal Project Grant award of $429,000.00 was made on August 1, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The goal of this research is to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells in order to develop novel therapies for this deadly disease. The research aims to identify GBM patient subsets...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $424,875 Project Grant under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders" to the University of Maryland, Baltimore to conduct research on the role of the TREM2 gene and mitochondrial function in microglia, the immune cells of the brain. The key objectives are to elucidate mitochondrial defects in TREM2-deficient human microglia, determine if the drug idebenone can...